MSB 3.21% $1.13 mesoblast limited

2023 The Final Countdown, page-3085

  1. 17,010 Posts.
    lightbulb Created with Sketch. 2412
    Yes, and with almost half of the patients in the aGVHD trial not having biomarkers to compare, the potential for bias in the results becomes even more significant.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.